Cabrera, Eric Escobar,Von Kreudenstein, Thomas Spreter,Dixit, Surjit Bhimarao,Lario, Paula Irene,Poon, David Kai Yuen,D'Angelo, Igor Edmondo Paolo
申请号：
HRP20192045
公开号：
HRP20192045T1
申请日:
2019.11.12
申请国别(地区):
HR
年份:
2020
代理人:
摘要：
The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.
